New Analysis Shows How The New Law Will Provide Average Savings of $7,590 To Some Cancer Patients With Medicare And Specifically To People Taking Seven High-Priced Cancer Drugs
“It’s Time For The Other Big Insulin Corporations To Follow Suit”
Patient Advocate Lisa Ann Wetzel-Trainor Moderated A Conversation Where Merith Answered Questions On Her Background, The Inflation Reduction Act, And P4AD’s Future Goals:
The following statement was issued by David Mitchell, a cancer patient and founder and president of Patients For Affordable Drugs, in response to the pricing of Relyvrio following the Food and Drug Administration’s approval of the drug combination to treat amyotrophic lateral sclerosis (ALS):
My name is Bob Parant, and I have been living with type 1 diabetes for 50 years. I am one of the 3.3 million Medicare beneficiaries who need insulin. I was diagnosed during what I call the “dark ages” of diabetes and have had many challenges along the way, including losing my leg.
Basey Has Devoted Her Career To Ensuring That Life-saving Medications Are Affordable And Accessible For All Who Need Them
My name is Jackie Trapp. I live in Muskego, WI and have been married for 34 years to my wonderful, loving husband. In August of 2015, I was diagnosed with multiple myeloma, an incurable blood cancer.
My name is Steven Hadfield. I am 70 years old, a long-time North Carolinian, a husband, a grandfather of three, and a football fanatic. I’m also a rare cancer and type 2 diabetes patient.
Patients For Affordable Drugs is the only independent national patient organization focused exclusively on achieving policy changes to lower the price of prescription drugs.
